ARWR
Price
$12.64
Change
+$0.45 (+3.69%)
Updated
Apr 2, 02:34 PM (EDT)
Capitalization
1.68B
36 days until earnings call
NTLA
Price
$7.30
Change
+$0.64 (+9.61%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
688.91M
29 days until earnings call
Ad is loading...

ARWR vs NTLA

Header iconARWR vs NTLA Comparison
Open Charts ARWR vs NTLABanner chart's image
Arrowhead Pharmaceuticals
Price$12.64
Change+$0.45 (+3.69%)
Volume$2.05K
Capitalization1.68B
Intellia Therapeutics
Price$7.30
Change+$0.64 (+9.61%)
Volume$66.47K
Capitalization688.91M
ARWR vs NTLA Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. NTLA commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Hold and NTLA is a Buy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (ARWR: $12.20 vs. NTLA: $6.66)
Brand notoriety: ARWR: Notable vs. NTLA: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 114% vs. NTLA: 152%
Market capitalization -- ARWR: $1.68B vs. NTLA: $688.91M
ARWR [@Biotechnology] is valued at $1.68B. NTLA’s [@Biotechnology] market capitalization is $688.91M. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, both ARWR and NTLA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 4 TA indicator(s) are bullish while NTLA’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 4 bullish, 5 bearish.
  • NTLA’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than NTLA.

Price Growth

ARWR (@Biotechnology) experienced а -17.14% price change this week, while NTLA (@Biotechnology) price change was -23.77% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.95%. For the same industry, the average monthly price growth was -7.12%, and the average quarterly price growth was -11.69%.

Reported Earning Dates

ARWR is expected to report earnings on May 08, 2025.

NTLA is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (-4.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($1.68B) has a higher market cap than NTLA($689M). ARWR YTD gains are higher at: -35.080 vs. NTLA (-42.925). NTLA has higher annual earnings (EBITDA): -523.98M vs. ARWR (-580.69M). NTLA has more cash in the bank: 602M vs. ARWR (553M). NTLA has less debt than ARWR: NTLA (210M) vs ARWR (525M). NTLA has higher revenues than ARWR: NTLA (57.9M) vs ARWR (2.5M).
ARWRNTLAARWR / NTLA
Capitalization1.68B689M243%
EBITDA-580.69M-523.98M111%
Gain YTD-35.080-42.92582%
P/E RatioN/AN/A-
Revenue2.5M57.9M4%
Total Cash553M602M92%
Total Debt525M210M250%
FUNDAMENTALS RATINGS
ARWR vs NTLA: Fundamental Ratings
ARWR
NTLA
OUTLOOK RATING
1..100
5358
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
9395
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (26) in the Biotechnology industry is significantly better than the same rating for ARWR (96). This means that NTLA’s stock grew significantly faster than ARWR’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ARWR (100). This means that NTLA’s stock grew similarly to ARWR’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as ARWR (100). This means that NTLA’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's Price Growth Rating (93) in the Biotechnology industry is in the same range as NTLA (95). This means that ARWR’s stock grew similarly to NTLA’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for NTLA (100). This means that ARWR’s stock grew significantly faster than NTLA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRNTLA
RSI
ODDS (%)
Bullish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
81%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 17 days ago
81%
Bullish Trend 10 days ago
79%
Declines
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PNVAX40.86N/A
N/A
Putnam International Capital Opp A
VEUSX87.71N/A
N/A
Vanguard European Stock Admiral
PWDIX9.50N/A
N/A
Donoghue Forlines Dividend I
PEIRX22.41N/A
N/A
Federated Hermes International Equity R6
BRBCX14.01-0.03
-0.21%
BlackRock Tactical Opportunities Inv C

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
-4.20%
DNLI - ARWR
56%
Loosely correlated
-9.60%
NTLA - ARWR
53%
Loosely correlated
-6.40%
BEAM - ARWR
50%
Loosely correlated
-9.70%
RGNX - ARWR
47%
Loosely correlated
-5.45%
CRNX - ARWR
47%
Loosely correlated
-8.71%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-6.40%
VCYT - NTLA
69%
Closely correlated
-0.30%
CRSP - NTLA
62%
Loosely correlated
-2.62%
BEAM - NTLA
62%
Loosely correlated
-9.70%
RXRX - NTLA
58%
Loosely correlated
-3.69%
FATE - NTLA
57%
Loosely correlated
-4.18%
More